Letwell Tablet contains Letrozole 2.5 mg, a non-steroidal aromatase inhibitor used primarily in the management of hormone receptor-positive breast cancer in postmenopausal women. Letrozole works by inhibiting the enzyme aromatase, which is responsible for the peripheral conversion of androgens to estrogens, thereby reducing circulating estrogen levels and limiting the growth of estrogen-dependent breast cancer cells. It is indicated for adjuvant treatment of early breast cancer, as well as for advanced or metastatic breast cancer in postmenopausal patients. Letrozole is also employed off-label for ovulation induction in women with anovulatory infertility. The recommended dosage is typically one 2.5 mg tablet once daily, with treatment duration and regimen tailored according to clinical response and physician discretion. Common adverse effects include hot flashes, arthralgia, fatigue, and nausea, while serious side effects may involve osteoporosis and cardiovascular events due to estrogen depletion. Caution is advised in patients with hepatic impairment, and it is contraindicated during pregnancy and lactation. Regular monitoring of bone mineral density and lipid profile is recommended during prolonged therapy. Letwell Tablet should be used under strict medical supervision to optimize therapeutic outcomes and minimize potential risks.